Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (19986)	5/4/1998 10:19:00 AM
From: bob zagorin	Respond to of 32384

Henry (or anyone), would you compare the cellular mechanism involved in anti-angiogenesis with that of anti-code as in Genta's program. Here is a paragraph recent Genta release as reference. Thanks. "...As an antisense compound, G3139 is designed to act toward a specific gene and prevent it from triggering the production of disease-related protein. G3139's target, the bcl-2 gene, interferes in the normal mortality of cells (apoptosis) and has been implicated in prostate cancer, non-Hodgkin's lymphoma, melanoma, breast and other cancers...."

To: Henry Niman who wrote (19986)	5/4/1998 2:53:00 PM
From: Mudcat	Read Replies (4) \| Respond to of 32384

<LGND has a very broad anti-angiogenesis program that targets MMPI's among other things (also selectins). The goal is to cut off blood supply and inhibit formation of new blood vessels by blocking MMPs (matrix metalloproteins)> Lgnd, as always, is stated to have very broad programs against this diesease and that disease but the stock price never moves up. Here is a prime example that the street has absolutely no confidence in LGND. Lgnd puts out mice model data on breast cancer and the stock doesn't move. Entremed puts out mice model data and they shoot from 12 to 80. Many comments on the financial news programs state cancer related stocks are getting a boost from the Entremed news, but as ussual Lgnd is unchanged. Not good in my opinion for a company whose main thrust is supposed to be cancer. Also saw the CEO from Entremd being interviewed by Joe Kernan. Why isn't Robinson out trying similar tactics to try to earn his huge salary?